Invizius Limited, a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution, in the Company’s first-in-human Phase 1 clinical study. The UK
Join Russell Fryer as he demonstrates how to manage capital gains tax with a Knowledge-Intensive (KI) EIS fund. This is technical tax planning webinar, which may be very relevant to your clients in the run up to the tax year end. *?????? ???? ??? ???? ???? ????????* Visit Mercia’s EIS area
Mercia Ventures, one of the UK’s most active investors, has expanded its platform to further support the expansion of its portfolio companies and help them gain entry into the competitive US marketplace. The service has been bolstered by the addition of two new Growth Partners, both of whom are based in the US and have years
Join Paul Mattick, as he discusses why many people prefer the Knowledge-Intensive (KI) EIS fund. The differences between an “unapproved” EIS fund and a “KI” EIS are small but are important, and provide interesting tax planning opportunities.
The adage “a team is only as strong as its weakest link” resonates profoundly within today’s complex supply chains. The rising frequency of cyberattacks in supply chains – a trend highlighted by Gartner’s prediction that by 2025, nearly half of all organiszations will experience attacks through their software supply chains – underscores this vulnerability. A
We feel privileged to have backed the Founders of over 100 software businesses at Seed to Series A over the years. Despite 2023 being one of the gloomiest years in venture in recent memory, we continued to be active, with new investments into Social Value Portal, Risk Ledger, Centuro Global, HowNow, Kuano, Envoke-Demos, Huler, FourJaw
Last year, Mercia Ventures spearheaded a £2 million investment into ImmuONE, the spin-out developing groundbreaking 3D human lung models that reduce reliance on animal testing. Before a new drug, chemical or product is launched, assessing safety for humans is crucial. Historically, this often meant testing on animals. Not only does this pose ethical concerns, but
Cell and gene based therapies are the next frontier in medicine. Unlike other therapies they have the potential to cure diseases as opposed to merely treating the disease, as is the case with more traditional treatment modalities. It feels like they almost belong in a sci-fi movie; genetically engineering a patient’s own cells or replacing
In this update, we’re digging into UK venture capital conditions and their impact, shedding light on crucial factors influencing EIS fund performance. We’ll also dive into why Mercia EIS is still holding up compared to the rest of the market and how our conservative valuation policy shields investors from significant adjustments to Net Asset Value
Managing Director of Mercia Ventures, Peter Dines, speaks to Wealth Club about the portfolio, recent investments, the Northern VCT investment approach, and the challenges and opportunities in the current economic climate. Recorded October 2023 with Wealth Club.